Businesses
Here's a look at documents from U.S. and international businesses
Businesses
Featured Stories
Xi Zhe Wuxi, Curio Collection by Hilton Opens, Bringing Century Old Jiangnan Story to Life
MCLEAN, Virginia, Sept. 5 -- Hilton Worldwide Holdings posted the following news release on Sept. 4, 2026:
* * *
Xi Zhe Wuxi, Curio Collection by Hilton Opens, Bringing Century Old Jiangnan Story to Life
Xi Zhe Wuxi, Curio Collection by Hilton opens, marking the brand's first property in Jiangsu Province.
Hilton continues to expand its lifestyle brand portfolio in China, now with five lifestyle brands.
The hotel blends a century-old historic residence with modern design, offering guests a unique Jiangnan cultural experience.
WUXI, China -- Hilton (NYSE: HLT) today announced the opening of ... Show Full Article MCLEAN, Virginia, Sept. 5 -- Hilton Worldwide Holdings posted the following news release on Sept. 4, 2026: * * * Xi Zhe Wuxi, Curio Collection by Hilton Opens, Bringing Century Old Jiangnan Story to Life Xi Zhe Wuxi, Curio Collection by Hilton opens, marking the brand's first property in Jiangsu Province. Hilton continues to expand its lifestyle brand portfolio in China, now with five lifestyle brands. The hotel blends a century-old historic residence with modern design, offering guests a unique Jiangnan cultural experience. WUXI, China -- Hilton (NYSE: HLT) today announced the opening ofXi Zhe Wuxi, Curio Collection by Hilton, marking Curio Collection by Hilton's first property in Jiangsu Province. Comprising a historic residence alongside a newly constructed building, the hotel's design embraces the coexistence of past and present, creating an urban retreat that blends historical heritage with contemporary comfort. Located within Wuxi Center 66, the hotel has been developed by Hang Lung Properties and is managed by Hilton.
The story of Xi Zhe Wuxi, Curio Collection by Hilton begins with a notable residence at No.118 Dongdajie Street. Built in 1933 by Wuxi entrepreneur Zhang Xiaocheng and his sister Zhang Chuquan, one of the city's early Western-trained obstetricians and gynaecologists, the residence has been reimagined nearly a century later alongside a newly constructed building to form today's hotel, blending Wuxi's heritage with contemporary design.
The name "Xi Zhe" is rich in meaning: "Xi" is derived from Wuxi, while "Zhe" combines two auspicious characters to symbolise double blessings. It also reflects the hotel's distinctive layout, where the new building and historic residence stand in harmony.
"Today's travellers are seeking stays that feel personal, authentic and deeply connected to their destination. Hilton's lifestyle brands are designed to meet these evolving expectations, offering differentiated experiences that give guests the freedom to express themselves, discover local culture and connect in meaningful ways," said Alexander Shockley, senior director, Lifestyle & Collection Brands, Asia Pacific, Hilton. "As we expand our lifestyle portfolio in China, we will continue to strengthen the positioning of our lifestyle brands and bring more distinctive experiences to travellers across the country."
The hotel is located in the heart of Wuxi's cultural heritage district, surrounded by historic landmarks including the former residences of Qian Zhongshu, Xue Fucheng and Hua Yanjun (Abing), and in close proximity to destinations such as Chong'an Temple, Nanchan Temple, Qingming Bridge Historical and Cultural District and Huishan Ancient Town. Together, these landmarks and the hotel's century-old story create a cultural journey for guests to discover Wuxi's heritage and local identity.
The hotel's design seeks to create a balance between history and modernity, incorporating the essence of Jiangnan traditional architecture into a contemporary hospitality setting. Upon arrival, the front desk draws inspiration from the traditional medicine cabinets commonly found in medical clinics of the past.
A spiral staircase in the lobby echoes the design of the original staircases in the former residence of Mr. Zhang Xiaocheng. Known as "Zhuanpan Lou" or "Zouma Lou", this architectural form represents a classic feature of traditional Wuxi architecture, adding a touch of Jiangnan charm from a bygone era to the space.
Winnie Zhu, general manager, Xi Zhe Wuxi, Curio Collection by Hilton, said, "The hotel blends the timeless charm of a Republic-era residence with modern travel experiences. Located in the cultural heart of Wuxi and surrounded by historic residences of notable figures, it offers guests an opportunity to slow down and immerse themselves in the elegant Jiangnan setting where the past and present coexist, creating a tranquil retreat for meaningful stays."
The hotel features 105 guest rooms and suites across the historic residence and contemporary building. Guest rooms bring a sense of tranquillity through surrounding garden views, with select rooms offering private courtyards. Terrazzo flooring and traditional lattice patterns echo Jiangnan residential architecture, while Art Deco-style carpets add a touch of Republic-era nostalgia.
Bedside lamps inspired by traditional palace lanterns create a warm ambience, while bamboo-textured headboards add refined tactile detail. Plum blossom-shaped stools, inspired by Wuxi's city flower, and Republic-era pendulum wall lamps further express the hotel's regional character.
The cultural experiences at the hotel extend beyond its architecture and interiors. SANWEI Bistro draws inspiration from Jiangnan culinary culture, combining authentic Wuxi flavours with contemporary culinary techniques. Purple clay tea rituals and Wuxi folk music performances create a delightful ambience infused with the charm of Jiangnan. Nestled within the former residence of Mr. Zhang Xiaocheng, Now and Then - French Bistro & Bar brings modern mixology into the residence's historic brick-and-wood architecture, creating a distinctive social space for guests. The Artist Center, located in a corner of the lobby, will also regularly host cultural programmes, continuing Wuxi's tradition of literary gatherings.
The hotel also features four swimming pools, comprising indoor and outdoor pools, hydrotherapy pools and a children's pool, with a dedicated pool bar. Amid the peaceful ambience of the pool, the hotel offers wellness experiences including sound bowl therapy and guided breathing sessions, providing guests with immersive moments of relaxation and rejuvenation. Other facilities for added convenience include a 24-hour fitness centre, multifunctional meeting spaces and pet-friendly service.
As travellers increasingly seek personalised experiences and deeper connections with destinations, lifestyle hotels have become one of the fastest-growing segments in China's hospitality market. To date, Hilton's lifestyle brands with open properties in China include Canopy Hotels, Curio Collection by Hilton, Tapestry Collection by Hilton and Motto by Hilton.
Curio Collection by Hilton is a portfolio of individually remarkable hotels, each with a bespoke story that is brought to life through distinctive interpretations of local culture and personalised guest experiences. Since opening its first Asia Pacific property in Sanya, China in 2017, the brand has expanded to destinations including Xiamen, Guangzhou, Hangzhou, Qingdao and Luoyang, becoming one of Hilton's fastest-growing lifestyle brands in China.
Xi Zhe Wuxi, Curio Collection by Hilton is located at No. 65 Jiankang Road, Liangxi District, Wuxi, Jiangsu Province, China. Guests can visit the official website or call +86 510 8989 8888 to make a reservation.
* * *
FAQ: Xi Zhe Wuxi, Curio Collection by Hilton Opens, Bringing Century-Old Jiangnan Story to Life
Where is Xi Zhe Wuxi, Curio Collection by Hilton located, and what cultural attractions are nearby?
The hotel is located at No.65 Jiankang Road, Liangxi District, Wuxi, in the heart of the city's central business district and approximately 300 metres from the nearest metro station. Surrounded by historic landmarks including the former residences of Qian Zhongshu, Xue Fucheng and Hua Yanjun (Abing), and close to cultural destinations such as Chong'an Temple, Nanchan Temple, Qingming Bridge Historical and Cultural District and Huishan Ancient Town, the hotel provides guests with an opportunity to explore Wuxi's rich heritage and cultural identity.
What is the unique design concept of Xi Zhe Wuxi, Curio Collection by Hilton?
The hotel embraces the design concept of "the coexistence of past and present," bringing together the former residence of Mr. Zhang Xiaocheng and contemporary architectural spaces to connect the city's historical memories with modern lifestyles. The design incorporates distinctive local elements, including traditional medicine cabinets, rotating staircases, palace lanterns, bamboo weaving patterns and Jiangnan gardens, reinterpreting them through a contemporary design language to bring new vitality to traditional culture within the hotel.
How can guests make a reservation at Xi Zhe Wuxi, Curio Collection by Hilton?
Xi Zhe Wuxi, Curio Collection by Hilton is located at No. 65 Jiankang Road, Liangxi District, Wuxi, Jiangsu Province, China. Guests can visit the official website or call +86 510 8989 8888 to learn more or make a reservation. Guests can also follow the hotel's official WeChat account, .
* * *
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 28 world-class brands comprising more than 9,400 properties and nearly 1.4 million rooms, in 144 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed over 4 billion guests in its more than 100-year history. Named as the No. 1 World's Best Workplace by Great Place to Work and Fortune, Hilton aims to create the best culture for its 500,000 team members around the world. Hilton has introduced industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the more than 260 million Hilton Honors members who book directly with Hilton can earn Points for hotel stays and experiences money can't buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit stories.hilton.com for more information, and connect with Hilton on Facebook, X, LinkedIn, Instagram and YouTube.
* * *
About Curio Collection by Hilton
Curio Collection by Hilton is a global portfolio of more than 200 individually remarkable hotels hand-picked to immerse guests in one-of-a-kind moments in the world's most sought-after destinations. Each hotel in the collection evokes a bespoke story through distinctive architecture and design, world-class food & beverage and curated experiences, while providing the benefits of Hilton and its award-winning guest loyalty program Hilton Honors. Experience Curio Collection by booking at curiocollection.com or through the industry-leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about Curio Collection by Hilton at stories.hilton.com/curio, and follow the brand on Facebook, Instagram and X.
* * *
Original text here: https://stories.hilton.com/releases/xi-zhe-wuxi-curio-collection-by-hilton-opens
[Category: BizTravel]
* * *
Xi Zhe Wuxi, Curio Collection by Hilton Opens, Bringing Century Old Jiangnan Story to Life
Xi Zhe Wuxi, Curio Collection by Hilton opens, marking the brand's first property in Jiangsu Province.
Hilton continues to expand its lifestyle brand portfolio in China, now with five lifestyle brands.
The hotel blends a century-old historic residence with modern design, offering guests a unique Jiangnan cultural experience.
WUXI, China -- Hilton (NYSE: HLT) today announced the opening of ... Show Full Article MCLEAN, Virginia, Sept. 5 -- Hilton Worldwide Holdings posted the following news release on Sept. 4, 2026: * * * Xi Zhe Wuxi, Curio Collection by Hilton Opens, Bringing Century Old Jiangnan Story to Life Xi Zhe Wuxi, Curio Collection by Hilton opens, marking the brand's first property in Jiangsu Province. Hilton continues to expand its lifestyle brand portfolio in China, now with five lifestyle brands. The hotel blends a century-old historic residence with modern design, offering guests a unique Jiangnan cultural experience. WUXI, China -- Hilton (NYSE: HLT) today announced the opening ofXi Zhe Wuxi, Curio Collection by Hilton, marking Curio Collection by Hilton's first property in Jiangsu Province. Comprising a historic residence alongside a newly constructed building, the hotel's design embraces the coexistence of past and present, creating an urban retreat that blends historical heritage with contemporary comfort. Located within Wuxi Center 66, the hotel has been developed by Hang Lung Properties and is managed by Hilton.
The story of Xi Zhe Wuxi, Curio Collection by Hilton begins with a notable residence at No.118 Dongdajie Street. Built in 1933 by Wuxi entrepreneur Zhang Xiaocheng and his sister Zhang Chuquan, one of the city's early Western-trained obstetricians and gynaecologists, the residence has been reimagined nearly a century later alongside a newly constructed building to form today's hotel, blending Wuxi's heritage with contemporary design.
The name "Xi Zhe" is rich in meaning: "Xi" is derived from Wuxi, while "Zhe" combines two auspicious characters to symbolise double blessings. It also reflects the hotel's distinctive layout, where the new building and historic residence stand in harmony.
"Today's travellers are seeking stays that feel personal, authentic and deeply connected to their destination. Hilton's lifestyle brands are designed to meet these evolving expectations, offering differentiated experiences that give guests the freedom to express themselves, discover local culture and connect in meaningful ways," said Alexander Shockley, senior director, Lifestyle & Collection Brands, Asia Pacific, Hilton. "As we expand our lifestyle portfolio in China, we will continue to strengthen the positioning of our lifestyle brands and bring more distinctive experiences to travellers across the country."
The hotel is located in the heart of Wuxi's cultural heritage district, surrounded by historic landmarks including the former residences of Qian Zhongshu, Xue Fucheng and Hua Yanjun (Abing), and in close proximity to destinations such as Chong'an Temple, Nanchan Temple, Qingming Bridge Historical and Cultural District and Huishan Ancient Town. Together, these landmarks and the hotel's century-old story create a cultural journey for guests to discover Wuxi's heritage and local identity.
The hotel's design seeks to create a balance between history and modernity, incorporating the essence of Jiangnan traditional architecture into a contemporary hospitality setting. Upon arrival, the front desk draws inspiration from the traditional medicine cabinets commonly found in medical clinics of the past.
A spiral staircase in the lobby echoes the design of the original staircases in the former residence of Mr. Zhang Xiaocheng. Known as "Zhuanpan Lou" or "Zouma Lou", this architectural form represents a classic feature of traditional Wuxi architecture, adding a touch of Jiangnan charm from a bygone era to the space.
Winnie Zhu, general manager, Xi Zhe Wuxi, Curio Collection by Hilton, said, "The hotel blends the timeless charm of a Republic-era residence with modern travel experiences. Located in the cultural heart of Wuxi and surrounded by historic residences of notable figures, it offers guests an opportunity to slow down and immerse themselves in the elegant Jiangnan setting where the past and present coexist, creating a tranquil retreat for meaningful stays."
The hotel features 105 guest rooms and suites across the historic residence and contemporary building. Guest rooms bring a sense of tranquillity through surrounding garden views, with select rooms offering private courtyards. Terrazzo flooring and traditional lattice patterns echo Jiangnan residential architecture, while Art Deco-style carpets add a touch of Republic-era nostalgia.
Bedside lamps inspired by traditional palace lanterns create a warm ambience, while bamboo-textured headboards add refined tactile detail. Plum blossom-shaped stools, inspired by Wuxi's city flower, and Republic-era pendulum wall lamps further express the hotel's regional character.
The cultural experiences at the hotel extend beyond its architecture and interiors. SANWEI Bistro draws inspiration from Jiangnan culinary culture, combining authentic Wuxi flavours with contemporary culinary techniques. Purple clay tea rituals and Wuxi folk music performances create a delightful ambience infused with the charm of Jiangnan. Nestled within the former residence of Mr. Zhang Xiaocheng, Now and Then - French Bistro & Bar brings modern mixology into the residence's historic brick-and-wood architecture, creating a distinctive social space for guests. The Artist Center, located in a corner of the lobby, will also regularly host cultural programmes, continuing Wuxi's tradition of literary gatherings.
The hotel also features four swimming pools, comprising indoor and outdoor pools, hydrotherapy pools and a children's pool, with a dedicated pool bar. Amid the peaceful ambience of the pool, the hotel offers wellness experiences including sound bowl therapy and guided breathing sessions, providing guests with immersive moments of relaxation and rejuvenation. Other facilities for added convenience include a 24-hour fitness centre, multifunctional meeting spaces and pet-friendly service.
As travellers increasingly seek personalised experiences and deeper connections with destinations, lifestyle hotels have become one of the fastest-growing segments in China's hospitality market. To date, Hilton's lifestyle brands with open properties in China include Canopy Hotels, Curio Collection by Hilton, Tapestry Collection by Hilton and Motto by Hilton.
Curio Collection by Hilton is a portfolio of individually remarkable hotels, each with a bespoke story that is brought to life through distinctive interpretations of local culture and personalised guest experiences. Since opening its first Asia Pacific property in Sanya, China in 2017, the brand has expanded to destinations including Xiamen, Guangzhou, Hangzhou, Qingdao and Luoyang, becoming one of Hilton's fastest-growing lifestyle brands in China.
Xi Zhe Wuxi, Curio Collection by Hilton is located at No. 65 Jiankang Road, Liangxi District, Wuxi, Jiangsu Province, China. Guests can visit the official website or call +86 510 8989 8888 to make a reservation.
* * *
FAQ: Xi Zhe Wuxi, Curio Collection by Hilton Opens, Bringing Century-Old Jiangnan Story to Life
Where is Xi Zhe Wuxi, Curio Collection by Hilton located, and what cultural attractions are nearby?
The hotel is located at No.65 Jiankang Road, Liangxi District, Wuxi, in the heart of the city's central business district and approximately 300 metres from the nearest metro station. Surrounded by historic landmarks including the former residences of Qian Zhongshu, Xue Fucheng and Hua Yanjun (Abing), and close to cultural destinations such as Chong'an Temple, Nanchan Temple, Qingming Bridge Historical and Cultural District and Huishan Ancient Town, the hotel provides guests with an opportunity to explore Wuxi's rich heritage and cultural identity.
What is the unique design concept of Xi Zhe Wuxi, Curio Collection by Hilton?
The hotel embraces the design concept of "the coexistence of past and present," bringing together the former residence of Mr. Zhang Xiaocheng and contemporary architectural spaces to connect the city's historical memories with modern lifestyles. The design incorporates distinctive local elements, including traditional medicine cabinets, rotating staircases, palace lanterns, bamboo weaving patterns and Jiangnan gardens, reinterpreting them through a contemporary design language to bring new vitality to traditional culture within the hotel.
How can guests make a reservation at Xi Zhe Wuxi, Curio Collection by Hilton?
Xi Zhe Wuxi, Curio Collection by Hilton is located at No. 65 Jiankang Road, Liangxi District, Wuxi, Jiangsu Province, China. Guests can visit the official website or call +86 510 8989 8888 to learn more or make a reservation. Guests can also follow the hotel's official WeChat account, .
* * *
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 28 world-class brands comprising more than 9,400 properties and nearly 1.4 million rooms, in 144 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed over 4 billion guests in its more than 100-year history. Named as the No. 1 World's Best Workplace by Great Place to Work and Fortune, Hilton aims to create the best culture for its 500,000 team members around the world. Hilton has introduced industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the more than 260 million Hilton Honors members who book directly with Hilton can earn Points for hotel stays and experiences money can't buy. With the free Hilton Honors app, guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit stories.hilton.com for more information, and connect with Hilton on Facebook, X, LinkedIn, Instagram and YouTube.
* * *
About Curio Collection by Hilton
Curio Collection by Hilton is a global portfolio of more than 200 individually remarkable hotels hand-picked to immerse guests in one-of-a-kind moments in the world's most sought-after destinations. Each hotel in the collection evokes a bespoke story through distinctive architecture and design, world-class food & beverage and curated experiences, while providing the benefits of Hilton and its award-winning guest loyalty program Hilton Honors. Experience Curio Collection by booking at curiocollection.com or through the industry-leading Hilton Honors app. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits. Learn more about Curio Collection by Hilton at stories.hilton.com/curio, and follow the brand on Facebook, Instagram and X.
* * *
Original text here: https://stories.hilton.com/releases/xi-zhe-wuxi-curio-collection-by-hilton-opens
[Category: BizTravel]
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
JERSEY CITY, New Jersey, Sept. 5 (TNSxrep) -- Verisk Analytics Inc., a data analytics provider, issued the following news on Sept. 4, 2026:
* * *
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Five-year Verisk CargoNet analysis underscores holiday exposure as theft methods become more selective and sophisticated
Key Takeaways
* Verisk CargoNet analyzed 273 theft events that occurred during the Labor Day holiday periods from 2021 through 2025.
* California, Texas, and Illinois were the most common states for activity, with major freight hubs ... Show Full Article JERSEY CITY, New Jersey, Sept. 5 (TNSxrep) -- Verisk Analytics Inc., a data analytics provider, issued the following news on Sept. 4, 2026: * * * Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks Five-year Verisk CargoNet analysis underscores holiday exposure as theft methods become more selective and sophisticated Key Takeaways * Verisk CargoNet analyzed 273 theft events that occurred during the Labor Day holiday periods from 2021 through 2025. * California, Texas, and Illinois were the most common states for activity, with major freight hubsand population centers continuing to drive risk.
* Theft activity clustered on the days framing the holiday rather than on the holiday weekend itself, with Thursday, Friday, Tuesday, and Wednesday accounting for 71% of all incidents.
* Verisk CargoNet warns that holiday risk now includes both traditional theft of unattended freight and evolving identity-based fraud involving compromised phone systems, carrier accounts, and compliance platforms.
-
As the Labor Day weekend approaches, cargo theft remains a persistent and elevated threat to freight moving across the United States. Verisk (Nasdaq: VRSK), a leading data analytics and technology provider to the global insurance industry, released an analysis today from its CargoNet business on Labor Day cargo theft incidents over the past five years. The analysis found that theft activity has settled at a materially higher baseline than at the start of the period, positioning the 2026 holiday weekend as another period of potentially heightened exposure.
Verisk CargoNet's review of incidents reported during the Thursday-before through Wednesday-after Labor Day shows sustained theft activity, concentrated exposure in major freight markets, and an expanding mix of traditional and identity-based theft methods.
Verisk CargoNet recorded 273 cargo theft incidents across the five-day Labor Day analysis periods from 2021 through 2025. The annual count rose from 33 incidents in 2021 to 56 in 2025, an increase of 70%, and reached a five-year high of 70 incidents in 2024.
The timing of theft within the holiday period underscores unique exposure risks. Friday was the single most active day with 55 incidents, followed by Tuesday with 49, Thursday with 46, and Wednesday with 44. Together, the four days surrounding the holiday weekend accounted for 194 of the 273 incidents, or 71% of the five-year total. The holiday weekend was comparatively quiet, with 24 incidents on Saturday, 28 on Sunday, and 27 on Labor Day Monday. The pattern is consistent with the growing share of cargo theft carried out through deceptive pickup and non-delivery schemes, which depend on live staff, active phone lines, and freight moving through normal business channels, conditions that largely disappear over a holiday weekend and return on either side of it.
The Labor Day threat is best understood as two overlapping risks. The first is physical exposure created when loaded freight sits at rest during closures or schedule disruptions. The second is verification exposure created when reduced staffing and time pressure make it easier for a criminal to impersonate a trusted carrier, alter shipment instructions, or insert fraudulent contact information into an otherwise legitimate transaction.
California, Texas, and Illinois accounted for 130 of the 273 incidents analyzed, or 48% of the five-year total. California led with 70 incidents, followed by Texas with 38 and Illinois with 22. This concentration is consistent with Verisk CargoNet's broader experience: theft activity clusters around dense freight networks, large consumer markets, intermodal infrastructure, and locations where stolen goods can be moved or resold quickly.
The commodity profile also reflects resale opportunity. Food and beverage shipments led with 49 incidents, followed by household goods with 27, electronics with 25, vehicles and accessories with 20, and metals with 11. These categories combine steady illicit-market demand with products that can often be broken down, redistributed, or sold through multiple channels.
Verisk CargoNet estimates total commodity value across the analysis at approximately $31.8 million.
Emerging Threat: Identity-Based Cargo Theft and Shipment Misdirection
Verisk CargoNet continues to observe organized groups combining traditional theft with technical deception. Criminals may compromise carrier accounts, software-based business phone systems, email accounts, or compliance-platform credentials so they can operate from inside channels that a broker or shipper normally considers trustworthy. This is more dangerous than simple spoofing because the fraudulent actor may possess authentic account access, recognizable contact details, and knowledge of active shipments.
The resulting theft may occur at tender, pickup, or after a legitimate carrier has taken possession. A criminal who changes a delivery address or contact after pickup can bypass controls that focus only on carrier selection.
In its July 4 holiday analysis, Verisk CargoNet estimated that cargo theft losses exceeded $359 million in the first six months of 2026 and that the average stolen commodity value had climbed to approximately $341,518. Incident counts alone no longer describe the full risk. Organized groups are demonstrating greater selectivity, pursuing high-value metals, enterprise technology components, and other freight that can produce an outsized return from a single successful theft.
* * *
Footnote: The Labor Day holiday analysis period consists of the Thursday before Labor Day through the Wednesday after Labor Day, 2021-2025.
* * *
About Verisk
Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global risks, including climate change, catastrophic events, sustainability and political issues. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk helps build global resilience for individuals, communities and businesses. With teams across more than 20 countries, Verisk consistently earns certification by Great Place to Work. For more, visit Verisk.com and the Verisk Newsroom.
* * *
Original text here: https://www.verisk.com/company/newsroom/verisk-cargonet-reports-persistent-labor-day-cargo-theft-exposure-across-u.s.-freight-networks/
[Category: BizConsulting]
* * *
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Five-year Verisk CargoNet analysis underscores holiday exposure as theft methods become more selective and sophisticated
Key Takeaways
* Verisk CargoNet analyzed 273 theft events that occurred during the Labor Day holiday periods from 2021 through 2025.
* California, Texas, and Illinois were the most common states for activity, with major freight hubs ... Show Full Article JERSEY CITY, New Jersey, Sept. 5 (TNSxrep) -- Verisk Analytics Inc., a data analytics provider, issued the following news on Sept. 4, 2026: * * * Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks Five-year Verisk CargoNet analysis underscores holiday exposure as theft methods become more selective and sophisticated Key Takeaways * Verisk CargoNet analyzed 273 theft events that occurred during the Labor Day holiday periods from 2021 through 2025. * California, Texas, and Illinois were the most common states for activity, with major freight hubsand population centers continuing to drive risk.
* Theft activity clustered on the days framing the holiday rather than on the holiday weekend itself, with Thursday, Friday, Tuesday, and Wednesday accounting for 71% of all incidents.
* Verisk CargoNet warns that holiday risk now includes both traditional theft of unattended freight and evolving identity-based fraud involving compromised phone systems, carrier accounts, and compliance platforms.
-
As the Labor Day weekend approaches, cargo theft remains a persistent and elevated threat to freight moving across the United States. Verisk (Nasdaq: VRSK), a leading data analytics and technology provider to the global insurance industry, released an analysis today from its CargoNet business on Labor Day cargo theft incidents over the past five years. The analysis found that theft activity has settled at a materially higher baseline than at the start of the period, positioning the 2026 holiday weekend as another period of potentially heightened exposure.
Verisk CargoNet's review of incidents reported during the Thursday-before through Wednesday-after Labor Day shows sustained theft activity, concentrated exposure in major freight markets, and an expanding mix of traditional and identity-based theft methods.
Verisk CargoNet recorded 273 cargo theft incidents across the five-day Labor Day analysis periods from 2021 through 2025. The annual count rose from 33 incidents in 2021 to 56 in 2025, an increase of 70%, and reached a five-year high of 70 incidents in 2024.
The timing of theft within the holiday period underscores unique exposure risks. Friday was the single most active day with 55 incidents, followed by Tuesday with 49, Thursday with 46, and Wednesday with 44. Together, the four days surrounding the holiday weekend accounted for 194 of the 273 incidents, or 71% of the five-year total. The holiday weekend was comparatively quiet, with 24 incidents on Saturday, 28 on Sunday, and 27 on Labor Day Monday. The pattern is consistent with the growing share of cargo theft carried out through deceptive pickup and non-delivery schemes, which depend on live staff, active phone lines, and freight moving through normal business channels, conditions that largely disappear over a holiday weekend and return on either side of it.
The Labor Day threat is best understood as two overlapping risks. The first is physical exposure created when loaded freight sits at rest during closures or schedule disruptions. The second is verification exposure created when reduced staffing and time pressure make it easier for a criminal to impersonate a trusted carrier, alter shipment instructions, or insert fraudulent contact information into an otherwise legitimate transaction.
California, Texas, and Illinois accounted for 130 of the 273 incidents analyzed, or 48% of the five-year total. California led with 70 incidents, followed by Texas with 38 and Illinois with 22. This concentration is consistent with Verisk CargoNet's broader experience: theft activity clusters around dense freight networks, large consumer markets, intermodal infrastructure, and locations where stolen goods can be moved or resold quickly.
The commodity profile also reflects resale opportunity. Food and beverage shipments led with 49 incidents, followed by household goods with 27, electronics with 25, vehicles and accessories with 20, and metals with 11. These categories combine steady illicit-market demand with products that can often be broken down, redistributed, or sold through multiple channels.
Verisk CargoNet estimates total commodity value across the analysis at approximately $31.8 million.
Emerging Threat: Identity-Based Cargo Theft and Shipment Misdirection
Verisk CargoNet continues to observe organized groups combining traditional theft with technical deception. Criminals may compromise carrier accounts, software-based business phone systems, email accounts, or compliance-platform credentials so they can operate from inside channels that a broker or shipper normally considers trustworthy. This is more dangerous than simple spoofing because the fraudulent actor may possess authentic account access, recognizable contact details, and knowledge of active shipments.
The resulting theft may occur at tender, pickup, or after a legitimate carrier has taken possession. A criminal who changes a delivery address or contact after pickup can bypass controls that focus only on carrier selection.
In its July 4 holiday analysis, Verisk CargoNet estimated that cargo theft losses exceeded $359 million in the first six months of 2026 and that the average stolen commodity value had climbed to approximately $341,518. Incident counts alone no longer describe the full risk. Organized groups are demonstrating greater selectivity, pursuing high-value metals, enterprise technology components, and other freight that can produce an outsized return from a single successful theft.
* * *
Footnote: The Labor Day holiday analysis period consists of the Thursday before Labor Day through the Wednesday after Labor Day, 2021-2025.
* * *
About Verisk
Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global risks, including climate change, catastrophic events, sustainability and political issues. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk helps build global resilience for individuals, communities and businesses. With teams across more than 20 countries, Verisk consistently earns certification by Great Place to Work. For more, visit Verisk.com and the Verisk Newsroom.
* * *
Original text here: https://www.verisk.com/company/newsroom/verisk-cargonet-reports-persistent-labor-day-cargo-theft-exposure-across-u.s.-freight-networks/
[Category: BizConsulting]
Tradeweb Reports August 2026 Total Trading Volume of $61.2 Trillion and Average Daily Volume of $2.8 Trillion
NEW YORK, Sept. 5 -- Tradeweb Markets, a builder and operator of global fixed income and derivatives marketplaces, issued the following news release on Sept. 4, 2026:
* * *
Tradeweb Reports August 2026 Total Trading Volume of $61.2 Trillion and Average Daily Volume of $2.8 Trillion
August 2026 ADV up 13.7% YoY
-
Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today reported total trading volume for the month of August 2026 of $61.2 trillion (tn). Average daily volume ("ADV") for the month was $2.8tn, an increase of 13.7 percent (%) year-over-year ... Show Full Article NEW YORK, Sept. 5 -- Tradeweb Markets, a builder and operator of global fixed income and derivatives marketplaces, issued the following news release on Sept. 4, 2026: * * * Tradeweb Reports August 2026 Total Trading Volume of $61.2 Trillion and Average Daily Volume of $2.8 Trillion August 2026 ADV up 13.7% YoY - Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today reported total trading volume for the month of August 2026 of $61.2 trillion (tn). Average daily volume ("ADV") for the month was $2.8tn, an increase of 13.7 percent (%) year-over-year("YoY").
August 2026 Highlights
rates
* U.S. government bond ADV was up 28.9% YoY to $282.5 billion (bn). European government bond ADV was up 22.2% YoY to $54.1bn.
- U.S. government bond ADV was driven by robust institutional and wholesale activity. Similarly, European government bond ADV was driven by strong volumes in our institutional client channel. Activity in both the U.S. and Europe was supported by a growing number of clients trading across a diverse set of trading protocols.
* Mortgage ADV was down 9.2% YoY to $210.7bn.
- To-Be-Announced ("TBA") activity moderated YoY as long-end Treasury yields moved sharply higher, with the number of accounts trading broadly unchanged. Tradeweb's specified pool platform saw its third-highest monthly trade count on record supported by a 10% YoY increase in accounts trading.
* Swaps/swaptions 1-year ADV was up 27.3% YoY to $553.0bn and total rates derivatives ADV was up 21.0% YoY to $1.1tn.
- Swaps/swaptions 1-year saw stronger risk trading activity YoY, driven by shifting global central bank policy expectations and persistent uncertainty surrounding the inflation and economic growth outlook. This was supported by a 30% YoY increase in compression activity, which carries a relatively lower fee per million ("FPM"). 3Q26 to date compression activity as a percentage of swaps/swaptions 1-year is trending lower than in 2Q26.
credit
* Fully electronic U.S. credit ADV was up 32.5% YoY to $8.9bn and European credit ADV was up 10.7% YoY to $2.0bn.
- U.S. credit volumes were driven by continued client adoption of trading protocols, most notably in Request-for-Quote ("RFQ"), Portfolio Trading ("PT"), and Tradeweb AllTrade(R). Tradeweb captured 19.0% share of fully electronic U.S. high grade TRACE and 8.3% share of U.S. high yield TRACE, as measured by Tradeweb. We also reported 26.8% total share of U.S. high grade TRACE and 10.0% total share of U.S. high yield TRACE. European credit volumes YoY were supported by continued use of a diverse set of trading protocols. Global cash credit PT ADV increased by 50.4% YoY, with non-comp PT[1] ADV up 113.1% YoY. PT carries a relatively lower FPM as compared to the broader cash credit average, with non-comp PT carrying a lower FPM than PT overall.
* Municipal bonds ADV was down 2.8% YoY to $523 million (mm).
- Municipal bond volumes lagged the broader market, which was up 1.1%[2] YoY driven by elevated new issuance activity which Tradeweb does not participate in.
* Credit derivatives ADV was up 51.4% YoY to $17.7bn.
- Increased hedge fund and systematic account activity YoY led to increased swap execution facility ("SEF") and multilateral trading facility ("MTF") credit default swaps activity.
equities
* U.S. ETF ADV was up 19.8% YoY to $10.1bn and International ETF ADV was up 23.6% YoY to $3.1bn.
- Stronger global ETF volumes YoY were driven by robust activity in our institutional and wholesale channels, as the client base grew and clients' adoption of Tradeweb's Automated Intelligent Execution ("AiEX") tool continued to grow YoY.
money markets
* Repo ADV was up 11.5% YoY to $836.3bn.
- Strong global repo ADV was supported by increased client participation across the platform YoY. In the U.S., strong growth was driven by a continued increase in net treasury issuance. Additionally, balances in the Fed's reverse repo facility ("RRP") remained close to zero, with a small spike at the end of the month. In Europe, strong trading momentum continued, supported by elevated collateral demand and shifting expectations surrounding major central bank policy rates.
* Other Money Markets ADV was down 0.1% YoY to $276.3bn.
- Other money markets ADV was driven by less client demand for commercial paper and discount notes YoY. This was offset by growth in Tradeweb's ICD Portal activity from both existing and new client additions.
Please refer to the report posted to https://www.tradeweb.com/newsroom/monthly-activity-reports/ for complete information and data related to our historical monthly, quarterly and yearly ADV and total trading volume across asset classes.
* * *
About Tradeweb Markets
Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 50 products to clients in the institutional, wholesale, retail and corporates markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves more than 3,000 clients in more than 85 countries. On average, Tradeweb facilitated more than $2.9 trillion in notional value traded per day over the past four fiscal quarters. For more information, please go to www.tradeweb.com.
Basis of Presentation
All reported amounts are presented in U.S. dollars, unless otherwise indicated. In determining the reported U.S. dollar amounts for non-U.S. dollar denominated securities, the non-U.S. dollar amount for a particular month is translated into U.S. dollars generally based on the monthly average foreign exchange rate for the prior month. Volumes presented in this release exclude volumes generated by (i) unbilled trial agreements, (ii) products billed on an agreement basis where we do not calculate notional value, and (iii) products that are not rates, credit, equities or money markets products. Please see the footnotes on page 3 of the full report for information regarding how we calculate market share amounts presented in this release.
Amounts for preliminary average variable fees per million dollars of volume traded and preliminary fixed fees for rates, credit, equities and money markets included in this release and in the related report are subject to the completion of management's final review and our other financial closing procedures and therefore are subject to change.
Beginning with the publication of the December 2024 Monthly Activity Report, Tradeweb adjusted its methodology for reflecting acquisitions in its reported average daily volume figures. For average daily volume derived from acquisitions, the denominator is now the number of trading days that have elapsed from the acquisition date to the end date of the reporting period, and not the total number of trading days in the reporting period, which was the previous methodology. Beginning in December 2024, this methodology was applied retroactively to restate the impact of both 2024 acquisitions; the average daily volume attributable to acquisitions occurring prior to 2024 was not restated.
Day counts generally reflect all SIFMA trading days, where applicable. As recommended by SIFMA, Good Friday, April 3, 2026 was an official trading day for U.S. Fixed Income markets. However, due to holiday-abbreviated hours (markets closed at 12:00 PM EDT) and limited trading activity, we have excluded April 3, 2026 as a trading day for all U.S. products. All trading volume from that day is included in April 2026 monthly totals.
Market and Industry Data
This release and the complete report include estimates regarding market and industry data that we prepared based on our management's knowledge and experience in the markets in which we operate, together with information obtained from various sources, including publicly available information, industry reports and publications, surveys, our clients, trade and business organizations and other contacts in the markets in which we operate. In presenting this information, we have made certain assumptions that we believe to be reasonable based on such data and other similar sources and on our knowledge of, and our experience to date in, the markets in which we operate. While such information is believed to be reliable for the purposes used herein, no representations are made as to the accuracy or completeness thereof and we take no responsibility for such information.
* * *
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading "Risk Factors" in the documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. In particular, preliminary average variable fees per million dollars of volume traded and preliminary fixed fees for rates, credit, equities and money markets are subject to the completion of management's final review and our other financial closing procedures and therefore are subject to change. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future events or performance and future events, our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if future events, our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of events, results or developments in future periods.
Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.
* * *
[1] Non-comp PT defined as a portfolio trade sent to a single dealer.
[2] Based on data from MSRB.
* * *
Original text here: https://www.tradeweb.com/newsroom/media-center/news-releases/tradeweb-reports-august-2026-total-trading-volume-of-$61.2-trillion-and-average-daily-volume-of-$2.8-trillion
[Category: BizFinancial Services]
* * *
Tradeweb Reports August 2026 Total Trading Volume of $61.2 Trillion and Average Daily Volume of $2.8 Trillion
August 2026 ADV up 13.7% YoY
-
Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today reported total trading volume for the month of August 2026 of $61.2 trillion (tn). Average daily volume ("ADV") for the month was $2.8tn, an increase of 13.7 percent (%) year-over-year ... Show Full Article NEW YORK, Sept. 5 -- Tradeweb Markets, a builder and operator of global fixed income and derivatives marketplaces, issued the following news release on Sept. 4, 2026: * * * Tradeweb Reports August 2026 Total Trading Volume of $61.2 Trillion and Average Daily Volume of $2.8 Trillion August 2026 ADV up 13.7% YoY - Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today reported total trading volume for the month of August 2026 of $61.2 trillion (tn). Average daily volume ("ADV") for the month was $2.8tn, an increase of 13.7 percent (%) year-over-year("YoY").
August 2026 Highlights
rates
* U.S. government bond ADV was up 28.9% YoY to $282.5 billion (bn). European government bond ADV was up 22.2% YoY to $54.1bn.
- U.S. government bond ADV was driven by robust institutional and wholesale activity. Similarly, European government bond ADV was driven by strong volumes in our institutional client channel. Activity in both the U.S. and Europe was supported by a growing number of clients trading across a diverse set of trading protocols.
* Mortgage ADV was down 9.2% YoY to $210.7bn.
- To-Be-Announced ("TBA") activity moderated YoY as long-end Treasury yields moved sharply higher, with the number of accounts trading broadly unchanged. Tradeweb's specified pool platform saw its third-highest monthly trade count on record supported by a 10% YoY increase in accounts trading.
* Swaps/swaptions 1-year ADV was up 27.3% YoY to $553.0bn and total rates derivatives ADV was up 21.0% YoY to $1.1tn.
- Swaps/swaptions 1-year saw stronger risk trading activity YoY, driven by shifting global central bank policy expectations and persistent uncertainty surrounding the inflation and economic growth outlook. This was supported by a 30% YoY increase in compression activity, which carries a relatively lower fee per million ("FPM"). 3Q26 to date compression activity as a percentage of swaps/swaptions 1-year is trending lower than in 2Q26.
credit
* Fully electronic U.S. credit ADV was up 32.5% YoY to $8.9bn and European credit ADV was up 10.7% YoY to $2.0bn.
- U.S. credit volumes were driven by continued client adoption of trading protocols, most notably in Request-for-Quote ("RFQ"), Portfolio Trading ("PT"), and Tradeweb AllTrade(R). Tradeweb captured 19.0% share of fully electronic U.S. high grade TRACE and 8.3% share of U.S. high yield TRACE, as measured by Tradeweb. We also reported 26.8% total share of U.S. high grade TRACE and 10.0% total share of U.S. high yield TRACE. European credit volumes YoY were supported by continued use of a diverse set of trading protocols. Global cash credit PT ADV increased by 50.4% YoY, with non-comp PT[1] ADV up 113.1% YoY. PT carries a relatively lower FPM as compared to the broader cash credit average, with non-comp PT carrying a lower FPM than PT overall.
* Municipal bonds ADV was down 2.8% YoY to $523 million (mm).
- Municipal bond volumes lagged the broader market, which was up 1.1%[2] YoY driven by elevated new issuance activity which Tradeweb does not participate in.
* Credit derivatives ADV was up 51.4% YoY to $17.7bn.
- Increased hedge fund and systematic account activity YoY led to increased swap execution facility ("SEF") and multilateral trading facility ("MTF") credit default swaps activity.
equities
* U.S. ETF ADV was up 19.8% YoY to $10.1bn and International ETF ADV was up 23.6% YoY to $3.1bn.
- Stronger global ETF volumes YoY were driven by robust activity in our institutional and wholesale channels, as the client base grew and clients' adoption of Tradeweb's Automated Intelligent Execution ("AiEX") tool continued to grow YoY.
money markets
* Repo ADV was up 11.5% YoY to $836.3bn.
- Strong global repo ADV was supported by increased client participation across the platform YoY. In the U.S., strong growth was driven by a continued increase in net treasury issuance. Additionally, balances in the Fed's reverse repo facility ("RRP") remained close to zero, with a small spike at the end of the month. In Europe, strong trading momentum continued, supported by elevated collateral demand and shifting expectations surrounding major central bank policy rates.
* Other Money Markets ADV was down 0.1% YoY to $276.3bn.
- Other money markets ADV was driven by less client demand for commercial paper and discount notes YoY. This was offset by growth in Tradeweb's ICD Portal activity from both existing and new client additions.
Please refer to the report posted to https://www.tradeweb.com/newsroom/monthly-activity-reports/ for complete information and data related to our historical monthly, quarterly and yearly ADV and total trading volume across asset classes.
* * *
About Tradeweb Markets
Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 50 products to clients in the institutional, wholesale, retail and corporates markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves more than 3,000 clients in more than 85 countries. On average, Tradeweb facilitated more than $2.9 trillion in notional value traded per day over the past four fiscal quarters. For more information, please go to www.tradeweb.com.
Basis of Presentation
All reported amounts are presented in U.S. dollars, unless otherwise indicated. In determining the reported U.S. dollar amounts for non-U.S. dollar denominated securities, the non-U.S. dollar amount for a particular month is translated into U.S. dollars generally based on the monthly average foreign exchange rate for the prior month. Volumes presented in this release exclude volumes generated by (i) unbilled trial agreements, (ii) products billed on an agreement basis where we do not calculate notional value, and (iii) products that are not rates, credit, equities or money markets products. Please see the footnotes on page 3 of the full report for information regarding how we calculate market share amounts presented in this release.
Amounts for preliminary average variable fees per million dollars of volume traded and preliminary fixed fees for rates, credit, equities and money markets included in this release and in the related report are subject to the completion of management's final review and our other financial closing procedures and therefore are subject to change.
Beginning with the publication of the December 2024 Monthly Activity Report, Tradeweb adjusted its methodology for reflecting acquisitions in its reported average daily volume figures. For average daily volume derived from acquisitions, the denominator is now the number of trading days that have elapsed from the acquisition date to the end date of the reporting period, and not the total number of trading days in the reporting period, which was the previous methodology. Beginning in December 2024, this methodology was applied retroactively to restate the impact of both 2024 acquisitions; the average daily volume attributable to acquisitions occurring prior to 2024 was not restated.
Day counts generally reflect all SIFMA trading days, where applicable. As recommended by SIFMA, Good Friday, April 3, 2026 was an official trading day for U.S. Fixed Income markets. However, due to holiday-abbreviated hours (markets closed at 12:00 PM EDT) and limited trading activity, we have excluded April 3, 2026 as a trading day for all U.S. products. All trading volume from that day is included in April 2026 monthly totals.
Market and Industry Data
This release and the complete report include estimates regarding market and industry data that we prepared based on our management's knowledge and experience in the markets in which we operate, together with information obtained from various sources, including publicly available information, industry reports and publications, surveys, our clients, trade and business organizations and other contacts in the markets in which we operate. In presenting this information, we have made certain assumptions that we believe to be reasonable based on such data and other similar sources and on our knowledge of, and our experience to date in, the markets in which we operate. While such information is believed to be reliable for the purposes used herein, no representations are made as to the accuracy or completeness thereof and we take no responsibility for such information.
* * *
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading "Risk Factors" in the documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. In particular, preliminary average variable fees per million dollars of volume traded and preliminary fixed fees for rates, credit, equities and money markets are subject to the completion of management's final review and our other financial closing procedures and therefore are subject to change. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future events or performance and future events, our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if future events, our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of events, results or developments in future periods.
Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.
* * *
[1] Non-comp PT defined as a portfolio trade sent to a single dealer.
[2] Based on data from MSRB.
* * *
Original text here: https://www.tradeweb.com/newsroom/media-center/news-releases/tradeweb-reports-august-2026-total-trading-volume-of-$61.2-trillion-and-average-daily-volume-of-$2.8-trillion
[Category: BizFinancial Services]
Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing
BOSTON, Massachusetts, Sept. 5 -- Ropes and Gray, a law firm, issued the following news:
* * *
Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing
Ropes & Gray represented Bain Capital Tech Opportunities as the lead investor in RQD* Clearing's $74 million minority growth investment. RQD/* is a clearing and custody firm providing the infrastructure that broker-dealers, RIAs, and foreign financial institutions need to access U.S. markets.
The investment was announced on Aug. 27.
Founded in 1984, Bain Capital is one of the world's leading private investment firms ... Show Full Article BOSTON, Massachusetts, Sept. 5 -- Ropes and Gray, a law firm, issued the following news: * * * Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing Ropes & Gray represented Bain Capital Tech Opportunities as the lead investor in RQD* Clearing's $74 million minority growth investment. RQD/* is a clearing and custody firm providing the infrastructure that broker-dealers, RIAs, and foreign financial institutions need to access U.S. markets. The investment was announced on Aug. 27. Founded in 1984, Bain Capital is one of the world's leading private investment firmswith 24 offices on four continents, more than 1,950 employees, and approximately $225 billion in assets under management.
Bain Capital's Tech Opportunities business aims to help growing technology companies reach their full potential.
The team was led by private capital transactions partner Elizabeth Gallucci and associate Andrea Daley and included private capital transactions partner Charlie Boer, asset management partner Brynn Rail, employment, executive compensation & benefits partner Renata Ferrari, IP transactions counsel Giancarlo Lee, and asset management associate Nathan McGuire.
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/09/ropes-gray-advised-bain-capital-in-strategic-growth-investment-in-rqd-clearing
[Category: BizLaw/Legal]
* * *
Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing
Ropes & Gray represented Bain Capital Tech Opportunities as the lead investor in RQD* Clearing's $74 million minority growth investment. RQD/* is a clearing and custody firm providing the infrastructure that broker-dealers, RIAs, and foreign financial institutions need to access U.S. markets.
The investment was announced on Aug. 27.
Founded in 1984, Bain Capital is one of the world's leading private investment firms ... Show Full Article BOSTON, Massachusetts, Sept. 5 -- Ropes and Gray, a law firm, issued the following news: * * * Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing Ropes & Gray represented Bain Capital Tech Opportunities as the lead investor in RQD* Clearing's $74 million minority growth investment. RQD/* is a clearing and custody firm providing the infrastructure that broker-dealers, RIAs, and foreign financial institutions need to access U.S. markets. The investment was announced on Aug. 27. Founded in 1984, Bain Capital is one of the world's leading private investment firmswith 24 offices on four continents, more than 1,950 employees, and approximately $225 billion in assets under management.
Bain Capital's Tech Opportunities business aims to help growing technology companies reach their full potential.
The team was led by private capital transactions partner Elizabeth Gallucci and associate Andrea Daley and included private capital transactions partner Charlie Boer, asset management partner Brynn Rail, employment, executive compensation & benefits partner Renata Ferrari, IP transactions counsel Giancarlo Lee, and asset management associate Nathan McGuire.
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/09/ropes-gray-advised-bain-capital-in-strategic-growth-investment-in-rqd-clearing
[Category: BizLaw/Legal]
Herbert Smith Freehills Kramer Advises Maurel & Prom on the Acquisition of Gran Tierra's Assets in Colombia and Ecuador
NEW YORK, Sept. 5 -- Herbert Smith Freehills Kramer LLP, a law firm, issued the following news:
* * *
Herbert Smith Freehills Kramer advises Maurel & Prom on the acquisition of Gran Tierra's assets in Colombia and Ecuador
Herbert Smith Freehills Kramer has advised Etablissements Maurel & Prom S.A. (M&P), an oil and gas company listed on Euronext Paris, on the signing of a Share Purchase Agreement for the acquisition of Gran Tierra's assets in Colombia and Ecuador, for a total transaction value of US$1.33 billion.
The transaction covers all of Gran Tierra's exploration and production assets ... Show Full Article NEW YORK, Sept. 5 -- Herbert Smith Freehills Kramer LLP, a law firm, issued the following news: * * * Herbert Smith Freehills Kramer advises Maurel & Prom on the acquisition of Gran Tierra's assets in Colombia and Ecuador Herbert Smith Freehills Kramer has advised Etablissements Maurel & Prom S.A. (M&P), an oil and gas company listed on Euronext Paris, on the signing of a Share Purchase Agreement for the acquisition of Gran Tierra's assets in Colombia and Ecuador, for a total transaction value of US$1.33 billion. The transaction covers all of Gran Tierra's exploration and production assetsin both countries, including producing fields, development projects and exploration licences. It represents a major strategic milestone for Maurel & Prom, significantly strengthening its presence in Latin America.
The total transaction value amounts to US$1.33 billion, including the assumption of certain debt instruments, including senior notes and a US$350 million prepayment facility entered into with Trafigura.
Completion of the transaction remains subject to obtaining the required regulatory approvals in Colombia and Ecuador and is expected to occur by the end of 2026.
Herbert Smith Freehills Kramer acted as legal counsel to Maurel & Prom on the corporate, energy, financing and tax aspects of this cross-border transaction.
The Herbert Smith Freehills Kramer team was led by partner Nina Bowyer on the Energy aspects.
The Paris team also included:
* Projects, Energy & Infrastructure: Amelie Dugast, Hennie Lui and Ayah Al-Sharari (associates), and Tendo Sebuyira (trainee solicitor);
* Corporate: Laurence Vincent (partner) and Nicolas Pegou (associate);
* Tax: Bruno Knadjian (partner) and Margaux Constantes (associate).
The international teams also included:
* Corporate (New York): Danielle MacGillivray (partner);
* Finance & Restructuring (New York): Edward Dougherty (partner) and Maria Falcao de Andrade (associate);
* Finance & Restructuring (London): Gabrielle Wong (partner), Alexander Yeagley (senior associate) and Monsiree Jirasarunya (consultant).
Maurel & Prom was also advised by Robalino Abogados on Ecuadorian law matters and by Chalela I Abogados S.A.S. on Colombian law matters. The seller was advised by Bracewell.
* * *
URL: Etablissements Maurel & Prom S.A.
* * *
Original text here: https://www.hsfkramer.com/news/2026-09/hsf-kramer-advises-maurel-prom-on-the-acquisition-of-gran-tierras-asset-in-colombia-and-ecuador
[Category: BizLaw/Legal]
* * *
Herbert Smith Freehills Kramer advises Maurel & Prom on the acquisition of Gran Tierra's assets in Colombia and Ecuador
Herbert Smith Freehills Kramer has advised Etablissements Maurel & Prom S.A. (M&P), an oil and gas company listed on Euronext Paris, on the signing of a Share Purchase Agreement for the acquisition of Gran Tierra's assets in Colombia and Ecuador, for a total transaction value of US$1.33 billion.
The transaction covers all of Gran Tierra's exploration and production assets ... Show Full Article NEW YORK, Sept. 5 -- Herbert Smith Freehills Kramer LLP, a law firm, issued the following news: * * * Herbert Smith Freehills Kramer advises Maurel & Prom on the acquisition of Gran Tierra's assets in Colombia and Ecuador Herbert Smith Freehills Kramer has advised Etablissements Maurel & Prom S.A. (M&P), an oil and gas company listed on Euronext Paris, on the signing of a Share Purchase Agreement for the acquisition of Gran Tierra's assets in Colombia and Ecuador, for a total transaction value of US$1.33 billion. The transaction covers all of Gran Tierra's exploration and production assetsin both countries, including producing fields, development projects and exploration licences. It represents a major strategic milestone for Maurel & Prom, significantly strengthening its presence in Latin America.
The total transaction value amounts to US$1.33 billion, including the assumption of certain debt instruments, including senior notes and a US$350 million prepayment facility entered into with Trafigura.
Completion of the transaction remains subject to obtaining the required regulatory approvals in Colombia and Ecuador and is expected to occur by the end of 2026.
Herbert Smith Freehills Kramer acted as legal counsel to Maurel & Prom on the corporate, energy, financing and tax aspects of this cross-border transaction.
The Herbert Smith Freehills Kramer team was led by partner Nina Bowyer on the Energy aspects.
The Paris team also included:
* Projects, Energy & Infrastructure: Amelie Dugast, Hennie Lui and Ayah Al-Sharari (associates), and Tendo Sebuyira (trainee solicitor);
* Corporate: Laurence Vincent (partner) and Nicolas Pegou (associate);
* Tax: Bruno Knadjian (partner) and Margaux Constantes (associate).
The international teams also included:
* Corporate (New York): Danielle MacGillivray (partner);
* Finance & Restructuring (New York): Edward Dougherty (partner) and Maria Falcao de Andrade (associate);
* Finance & Restructuring (London): Gabrielle Wong (partner), Alexander Yeagley (senior associate) and Monsiree Jirasarunya (consultant).
Maurel & Prom was also advised by Robalino Abogados on Ecuadorian law matters and by Chalela I Abogados S.A.S. on Colombian law matters. The seller was advised by Bracewell.
* * *
URL: Etablissements Maurel & Prom S.A.
* * *
Original text here: https://www.hsfkramer.com/news/2026-09/hsf-kramer-advises-maurel-prom-on-the-acquisition-of-gran-tierras-asset-in-colombia-and-ecuador
[Category: BizLaw/Legal]
Etcamah in Combination With a CDK4/6 Inhibitor Approved in the U.S. for 1st-line Advanced HR-positive Breast Cancer
WILMINGTON, Delaware, Sept. 5 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ETCAMAH(R) (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation
Innovative treatment strategy has potential to reshape 1st-line treatment paradigm for patients in this setting
-
AstraZeneca's ETCAMAH(R) (camizestrant) in combination ... Show Full Article WILMINGTON, Delaware, Sept. 5 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * ETCAMAH(R) (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation Innovative treatment strategy has potential to reshape 1st-line treatment paradigm for patients in this setting - AstraZeneca's ETCAMAH(R) (camizestrant) in combinationwith a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized test.
The accelerated approval was based on results from the pivotal SERENA-6 Phase III trial presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine.1
Kevin Kalinsky, MD, MS, FASCO, Division Director of Medical Oncology, Winship Cancer Institute of Emory University and investigator for the trial, said: "The combination provides an important new option for the one in three patients with this form of advanced breast cancer whose tumors develop ESR1 mutations before clinical or radiographic disease progression. Today's approval will enable clinicians to promptly intervene and change therapeutic strategy at an earlier opportunity ahead of disease progression, rather than waiting until the cancer becomes harder to treat, and patient outcomes and quality of life worsen."
Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: "Today's approval is the tenth granted by the FDA this year across AstraZeneca's portfolio and our fourth in breast cancer alone. The ETCAMAH combination reflects AstraZeneca's leadership in redefining breast cancer care by pioneering a new approach using circulating tumor DNA and is the first and only medicine of its type in the 1st-line setting."
In a planned interim analysis of the SERENA-6 trial, ETCAMAH in combination with a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% versus standard-of-care treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (based on a hazard ratio [HR] of 0.44; 95% confidence interval [CI]:0.31-0.60; p<0.00001; median PFS 16.0 versus 9.2 months). While data for the key secondary endpoints of time to second disease progression (PFS2) and overall survival (OS) were immature at the time of the interim analysis, a subsequent pre-planned analysis demonstrated a statistically significant and clinically meaningful PFS2 benefit of 25.7 months versus 19.1 months in favor of the ETCAMAH combination (HR: 0.63; 95% CI: 0.46-0.86; p=0.00373) and OS continued to mature in favor of the ETCAMAH combination (HR: 0.87; 95% CI: 0.57-1.30). The trial will continue to assess OS as a key secondary endpoint.
The safety profile of ETCAMAH in combination with palbociclib, ribociclib or abemaciclib in the SERENA-6 trial was consistent with the known safety profile of each medicine. No new safety concerns were identified, and discontinuations were very low and similar in both arms.1
In the US, breast cancer is the most common cancer in women, with more than 300,000 new patients diagnosed annually, and more than 42,000 deaths.2 Approximately 37,000 patients with HR-positive metastatic breast cancer in the US are treated with a medicine in the 1st-line setting; most frequently with endocrine therapies that target estrogen receptor (ER)-driven disease, which are often paired with CDK4/6 inhibitors.3-5 However, resistance to these therapies frequently develop in many patients.5 Once this occurs, treatment options are limited and survival rates are low with just over a third of patients anticipated to live beyond five years after diagnosis.5,6 Mutations in the ESR1 gene are a key driver of endocrine resistance and are associated with poor outcomes, emerging during treatment of the disease and becoming more prevalent as the disease progresses.7,8 Approximately 30% of patients with endocrine sensitive HR-positive disease develop ESR1 mutations during 1st-line treatment before disease progression.3
Concurrently with this approval, the FDA also approved a companion diagnostic test to detect emerging ESR1 resistance mutations in the circulating tumor DNA (ctDNA) of patients with HR-positive, HER2-negative advanced or metastatic breast cancer. SERENA-6 is the first global, double-blind, registrational Phase III trial to use a ctDNA-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before disease progression. The innovative trial design used ctDNA monitoring via a blood test at the time of routine tumor scans every two to three months to identify patients for early signs of endocrine resistance via the emergence of ESR1 mutations. Following detection of an ESR1 mutation without disease progression, the endocrine therapy of patients was switched to ETCAMAH from ongoing treatment with an AI, while continuing combination with the same CDK4/6 inhibitor.
ETCAMAH is also approved in more than 30 countries across the globe, including in the EU, Japan, Canada, the UK and several other countries based on the SERENA-6 Phase III trial.
IMPORTANT SAFETY INFORMATION
WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS
ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes (TdP), other ventricular arrhythmias, and sudden death.
Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of TdP. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently.
Obtain electrocardiogram (ECG) prior to initiation and monitor heart rate (HR) and QTc interval during treatment. Assess and correct electrolyte abnormalities prior to initiation and during treatment. Withhold ETCAMAH until resolution of QTc interval prolongation and resume or permanently discontinue ETCAMAH based on severity.
QTc Interval Prolongation: ETCAMAH in combination with a CDK4/6 inhibitor (CDK4/6i)
is associated with QTc interval prolongation. When ETCAMAH is used in combination with ribociclib, a CDK4/6i, there is potential for increased risk of TdP, other ventricular arrhythmias, and sudden death. One Grade 4 case of TdP was observed in a dose-finding trial when ETCAMAH was used with ribociclib. In SERENA-6, QTc interval prolongation occurred in 2.6% of patients treated with ETCAMAH in combination with a CDK4/6i. QTc interval prolongation led to dose interruption in 0.6% of patients. No patients in SERENA-6 discontinued ETCAMAH due to QTc interval prolongation. ETCAMAH also causes bradycardia, which increases the risk of QTc interval prolongation.
Perform an ECG prior to initiating ETCAMAH, then every week for the first 2 weeks of treatment, and periodically during treatment as clinically indicated. Obtain serum electrolytes at baseline and during treatment as clinically indicated, and correct electrolyte abnormalities. Avoid concomitant use of ETCAMAH in combination with a CDK4/6i with products that cause QTc interval prolongation, are strong CYP3A inhibitors, and/or are drugs known to lower HR.
For QTc >500 msec or QTc >480 msec and prolongation from baseline >60 msec, withhold ETCAMAH. If other contributing causes are identified, then treat or correct the contributing causes. Resume ETCAMAH when QTc returns to <480 msec. Reassess ECGs weekly for the first 2 weeks of treatment, and periodically during treatment as clinically indicated. Permanently discontinue ETCAMAH if QTc interval prolongation is either >500 msec or >60 msec change from baseline AND associated with any: TdP, polymorphic ventricular tachycardia, syncope, or signs/symptoms of serious arrhythmia.
Bradycardia: ETCAMAH causes a decrease in HR. Bradycardia increases the risk for life-threatening arrhythmias and sudden death when concomitant QTc interval prolongation is present, such as when ETCAMAH is used in combination with ribociclib, both a QTc interval prolonging product and a strong CYP3A inhibitor. In SERENA-6, bradycardia occurred in 8% of patients. The mean HR decrease from baseline was approximately 13 beats per minute (bpm) with the maximum decrease observed on day 15. Median time to onset was 17 days (range 13 to 283) after starting ETCAMAH. No patients discontinued ETCAMAH due to bradycardia. Dose interruption occurred in 3.9% of patients. The safety of ETCAMAH has not been established in patients with a baseline resting HR <55 bpm as these patients were excluded from SERENA-6. Monitor HR more frequently during the first 30 days of treatment in patients with bradycardia (HR <60 bpm) at baseline and those on concomitant medications known to lower HR (eg, beta-blockers).
For symptomatic (Grade 2 or above) bradycardia, withhold ETCAMAH until symptoms resolve. Obtain ECG to evaluate etiology. If a contributing concomitant medication is identified, modify the dosage or discontinue this medication, as appropriate, until bradycardia symptoms resolve, then resume ETCAMAH. Consider reassessing the HR after restart. Permanently discontinue for persistent symptomatic bradycardia.
Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ETCAMAH can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with ETCAMAH and for 4 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ETCAMAH and for 1 week after the last dose.
ADVERSE REACTIONS
The most common (20%) adverse reactions, including laboratory abnormalities, with ETCAMAH in combination with a CDK4/6i were decreased neutrophils (68%), decreased leukocytes (66%), decreased hemoglobin (47%), decreased lymphocytes (39%), decreased platelets (36%), visual disturbances (34%), and fatigue (23%).
Permanent discontinuation due to adverse reactions occurred in 1.3% of patients. Adverse reactions that resulted in permanent discontinuation of ETCAMAH included gastroesophageal reflux disease, cholestasis and hepatic cytolysis (0.6% each). Dosage interruption of ETCAMAH due to adverse reactions occurred in 22% of patients.
Visual disturbances: For visual disturbances limiting instrumental ADLs (activities of daily living) (Grade 2) or above, withhold ETCAMAH until symptoms resolve to Grade 1 or below. Refer to an eye professional for an ophthalmic examination and treatment and reassess at the next visit.
For other Grade 3 or higher adverse reactions: Withhold ETCAMAH until resolution to Grade 2 or below, then resume. Permanently discontinue for recurrence of Grade 3 or higher adverse reactions.
DRUG INTERACTIONS
* Strong CYP3A Inhibitors: Monitor for increased adverse reactions to ETCAMAH and modify the dosage as recommended
* Strong and Moderate CYP3A Inducers: Avoid the use of strong CYP3A inducers. Use caution with the co-administration of a moderate CYP3A inducer
- Avoid concomitant use of moderate CYP3A inducers for patients who are receiving ETCAMAH in combination with abemaciclib or palbociclib. If concomitant use cannot be avoided, increase the ETCAMAH dosage from 75 mg once daily to 150 mg once daily. After the moderate CYP3A inducer has been discontinued for at least 14 days, resume the ETCAMAH dosage used prior to initiation of the moderate CYP3A inducer
- For patients who are receiving ETCAMAH in combination with ribociclib concomitantly with a moderate CYP3A inducer, no ETCAMAH dosage modification is recommended
* CYP2C9 and/or CYP2C19 Substrates: Avoid concomitant use of ETCAMAH with CYP2C9 or CYP2C19 substrates during treatment with ETCAMAH and at least 2 weeks after the last dose of ETCAMAH, unless otherwise recommended in the Prescribing Information of the CYP2C9 or CYP2C19 substrate
* Certain CYP3A Substrates: Refer to the Prescribing Information for CYP3A substrates where minimal increases in the concentration may lead to serious adverse reactions
* Drugs that Prolong the QTc Interval: ETCAMAH is indicated in combination with a CDK4/6i and there is increased risk of QTc interval prolongation with ribociclib, a strong CYP3A inhibitor that can prolong the QTc interval. Refer to the ribociclib Prescribing Information for dosage modifications. Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of TdP. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently. ETCAMAH in combination with a CDK4/6i is associated with QTc interval prolongation
* Drugs that Cause Bradycardia: Avoid concomitant use of ETCAMAH with other products known to cause bradycardia. Monitor for signs and symptoms of bradycardia if concomitant use cannot be avoided. ETCAMAH causes decreases in HR that are dose and baseline HR dependent
Refer to the Prescribing Information for the co-administered CDK4/6i for dosage modification guidelines related to adverse reactions, organ impairment, and drug-drug interactions.
SPECIAL POPULATIONS
Pregnancy: Based on findings in animals and mechanism of action, ETCAMAH can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
Lactation: Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ETCAMAH and for 1 week after the last dose.
Females and Males of Reproductive Potential: ETCAMAH can cause fetal harm when administered to pregnant women. Verify pregnancy status of female patients of reproductive potential prior to initiating ETCAMAH. Advise female patients of reproductive potential to use effective non-hormonal contraception during treatment with ETCAMAH and for 4 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ETCAMAH and for 1 week after the last dose. Refer to the Prescribing Information of the CDK4/6i palbociclib, if used in combination with ETCAMAH, for contraception information and use for the longest recommended post-treatment duration. ETCAMAH may impair fertility in female and male patients.
Pediatric Use: Safety and effectiveness have not been established in pediatric patients.
Hepatic Impairment: In patients with severe (Child-Pugh C) hepatic impairment, when ETCAMAH is combined with ribociclib, reduce the dosing frequency to every other day.
No dosage modifications are required in other patients with hepatic impairment of any level, or when ETCAMAH is combined with abemaciclib or palbociclib, although patients with moderate or severe hepatic impairment (Child-Pugh B or C) should be monitored for increased adverse reactions and dosage modified as recommended.
INDICATION
ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Please see full Prescribing Information (https://www.azpicentral.com/pi.html?product=etcamah), including Boxed WARNING, and Patient Information (https://www.azpicentral.com/pi.html?product=etcamah&medguide=y) for ETCAMAH.
* * *
Notes
HR-positive breast cancer
Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.9 More than two million patients were diagnosed with breast cancer in 2024, with more than 690,000 deaths globally.9 While survival rates are high for those diagnosed with early breast cancer, only about 30% of patients diagnosed with or who progress to metastatic disease are expected to live five years following diagnosis.6
HR-positive breast cancer, characterized by the expression of estrogen or progesterone receptors, or both, is the most common subtype of breast cancer with 70% of tumors considered HR-positive and HER2-negative.6 ERs often drive the growth of HR-positive breast cancer cells.10
Globally, more than 200,000 patients with HR-positive breast cancer are treated with a medicine in the 1st-line setting; most frequently with endocrine therapies that target ER-driven disease, which are often paired with CDK4/6 inhibitors.3-5
The optimization of endocrine therapy and overcoming resistance to enable patients to continue benefiting from these treatments, as well as identifying new therapies for those who are less likely to benefit, are active areas of focus for breast cancer research.
SERENA-6
SERENA-6 is a Phase III, double-blind, randomized trial evaluating the efficacy and safety of ETCAMAH in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with HR-positive, HER2-negative advanced breast cancer (patients with either locally advanced disease, or metastatic disease) whose tumors have an emergent ESR1 mutation.
The global trial enrolled 315 adult patients with histologically confirmed HR-positive, HER2-negative advanced breast cancer, undergoing treatment with an AI in combination with a CDK4/6 inhibitor as 1st-line treatment. The primary endpoint of the SERENA-6 trial is PFS as assessed by investigator, with secondary endpoints including OS, and PFS2 by investigator assessment.
ETCAMAH(R) (camizestrant)
ETCAMAH is a potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist, administered orally, once daily. The recommended dose of ETCAMAH in combination with a CDK4/6 inhibitor is 75 mg.
ETCAMAH in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) is approved in the US, EU, Japan and several other countries for the treatment of adult patients with HR-positive (or ER-positive), HER2-negative locally advanced or metastatic breast cancer upon detection or emergence of ESR1 mutation and without disease progression during 1st-line endocrine therapy based on the results from the SERENA-6 Phase III trial.
The broad, robust and innovative ETCAMAH clinical development program, including the SERENA-4, CAMBRIA-1 and CAMBRIA-2 Phase III trials, is evaluating the safety and efficacy of ETCAMAH when used as a monotherapy or in combination with CDK4/6 inhibitors to address a number of areas of unmet need in HR-positive, HER2-negative breast cancer.
* * *
AstraZeneca in breast cancer
Driven by a growing understanding of breast cancer biology, AstraZeneca is challenging, and redefining, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need - with the bold ambition to one day eliminate breast cancer as a cause of death.
AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumor environment.
With fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines fulvestrant and goserelin and aims to reshape the HR-positive space with first-in-class AKT inhibitor, capivasertib, the TROP-2-directed ADC, datopotamab deruxtecan-dlnk and next-generation oral SERD, ETCAMAH.
PARP inhibitor olaparib is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to research olaparib in these settings. AstraZeneca is also exploring the potential of saruparib, a potent and selective inhibitor of PARP1, in combination with ETCAMAH in BRCA-mutated, HR-positive, HER2-negative advanced breast cancer.
To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is collaborating with Daiichi Sankyo to evaluate the potential of datopotamab deruxtecan-dlnk alone and in combination with immunotherapy durvalumab.
* * *
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
* * *
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.
* * *
References
1. Bidard FC, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med 2025; DOI: 10.1056/NEJMoa2502929.
2. American Cancer Society. Key Statistics for Breast Cancer. Available at: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html. Accessed September 2026.
3. Cerner CancerMPact database. Accessed September 2026.
4. Lin M, et al. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer. 2020; 10.7150/jca.48944.
5. Lloyd M R, et al. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022; 28(5):821-30.
6. National Cancer Institute. Cancer Stat facts: Female breast cancer subtypes. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed September 2026.
7. Brett O, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor positive breast cancer. Breast Cancer Res. 2021; 23:85.
8. Zundelevich A, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020; 22:16.
9. Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026; DOI: 10.3322/caac.70090.
10. Scabia V, et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nat Commun. 2022; 10.1038/s41467-022-30898-0.
* * *
Original text here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/ETCAMAH-camizestrant-in-combination-with-a-CDK-4-6-inhibitor-approved-in-the-US-for-1st-line-advanced-HR-positive-breast-cancer.html
[Category: BizPharmaceuticals]
* * *
ETCAMAH(R) (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation
Innovative treatment strategy has potential to reshape 1st-line treatment paradigm for patients in this setting
-
AstraZeneca's ETCAMAH(R) (camizestrant) in combination ... Show Full Article WILMINGTON, Delaware, Sept. 5 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * ETCAMAH(R) (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation Innovative treatment strategy has potential to reshape 1st-line treatment paradigm for patients in this setting - AstraZeneca's ETCAMAH(R) (camizestrant) in combinationwith a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized test.
The accelerated approval was based on results from the pivotal SERENA-6 Phase III trial presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine.1
Kevin Kalinsky, MD, MS, FASCO, Division Director of Medical Oncology, Winship Cancer Institute of Emory University and investigator for the trial, said: "The combination provides an important new option for the one in three patients with this form of advanced breast cancer whose tumors develop ESR1 mutations before clinical or radiographic disease progression. Today's approval will enable clinicians to promptly intervene and change therapeutic strategy at an earlier opportunity ahead of disease progression, rather than waiting until the cancer becomes harder to treat, and patient outcomes and quality of life worsen."
Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: "Today's approval is the tenth granted by the FDA this year across AstraZeneca's portfolio and our fourth in breast cancer alone. The ETCAMAH combination reflects AstraZeneca's leadership in redefining breast cancer care by pioneering a new approach using circulating tumor DNA and is the first and only medicine of its type in the 1st-line setting."
In a planned interim analysis of the SERENA-6 trial, ETCAMAH in combination with a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% versus standard-of-care treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (based on a hazard ratio [HR] of 0.44; 95% confidence interval [CI]:0.31-0.60; p<0.00001; median PFS 16.0 versus 9.2 months). While data for the key secondary endpoints of time to second disease progression (PFS2) and overall survival (OS) were immature at the time of the interim analysis, a subsequent pre-planned analysis demonstrated a statistically significant and clinically meaningful PFS2 benefit of 25.7 months versus 19.1 months in favor of the ETCAMAH combination (HR: 0.63; 95% CI: 0.46-0.86; p=0.00373) and OS continued to mature in favor of the ETCAMAH combination (HR: 0.87; 95% CI: 0.57-1.30). The trial will continue to assess OS as a key secondary endpoint.
The safety profile of ETCAMAH in combination with palbociclib, ribociclib or abemaciclib in the SERENA-6 trial was consistent with the known safety profile of each medicine. No new safety concerns were identified, and discontinuations were very low and similar in both arms.1
In the US, breast cancer is the most common cancer in women, with more than 300,000 new patients diagnosed annually, and more than 42,000 deaths.2 Approximately 37,000 patients with HR-positive metastatic breast cancer in the US are treated with a medicine in the 1st-line setting; most frequently with endocrine therapies that target estrogen receptor (ER)-driven disease, which are often paired with CDK4/6 inhibitors.3-5 However, resistance to these therapies frequently develop in many patients.5 Once this occurs, treatment options are limited and survival rates are low with just over a third of patients anticipated to live beyond five years after diagnosis.5,6 Mutations in the ESR1 gene are a key driver of endocrine resistance and are associated with poor outcomes, emerging during treatment of the disease and becoming more prevalent as the disease progresses.7,8 Approximately 30% of patients with endocrine sensitive HR-positive disease develop ESR1 mutations during 1st-line treatment before disease progression.3
Concurrently with this approval, the FDA also approved a companion diagnostic test to detect emerging ESR1 resistance mutations in the circulating tumor DNA (ctDNA) of patients with HR-positive, HER2-negative advanced or metastatic breast cancer. SERENA-6 is the first global, double-blind, registrational Phase III trial to use a ctDNA-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before disease progression. The innovative trial design used ctDNA monitoring via a blood test at the time of routine tumor scans every two to three months to identify patients for early signs of endocrine resistance via the emergence of ESR1 mutations. Following detection of an ESR1 mutation without disease progression, the endocrine therapy of patients was switched to ETCAMAH from ongoing treatment with an AI, while continuing combination with the same CDK4/6 inhibitor.
ETCAMAH is also approved in more than 30 countries across the globe, including in the EU, Japan, Canada, the UK and several other countries based on the SERENA-6 Phase III trial.
IMPORTANT SAFETY INFORMATION
WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS
ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes (TdP), other ventricular arrhythmias, and sudden death.
Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of TdP. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently.
Obtain electrocardiogram (ECG) prior to initiation and monitor heart rate (HR) and QTc interval during treatment. Assess and correct electrolyte abnormalities prior to initiation and during treatment. Withhold ETCAMAH until resolution of QTc interval prolongation and resume or permanently discontinue ETCAMAH based on severity.
QTc Interval Prolongation: ETCAMAH in combination with a CDK4/6 inhibitor (CDK4/6i)
is associated with QTc interval prolongation. When ETCAMAH is used in combination with ribociclib, a CDK4/6i, there is potential for increased risk of TdP, other ventricular arrhythmias, and sudden death. One Grade 4 case of TdP was observed in a dose-finding trial when ETCAMAH was used with ribociclib. In SERENA-6, QTc interval prolongation occurred in 2.6% of patients treated with ETCAMAH in combination with a CDK4/6i. QTc interval prolongation led to dose interruption in 0.6% of patients. No patients in SERENA-6 discontinued ETCAMAH due to QTc interval prolongation. ETCAMAH also causes bradycardia, which increases the risk of QTc interval prolongation.
Perform an ECG prior to initiating ETCAMAH, then every week for the first 2 weeks of treatment, and periodically during treatment as clinically indicated. Obtain serum electrolytes at baseline and during treatment as clinically indicated, and correct electrolyte abnormalities. Avoid concomitant use of ETCAMAH in combination with a CDK4/6i with products that cause QTc interval prolongation, are strong CYP3A inhibitors, and/or are drugs known to lower HR.
For QTc >500 msec or QTc >480 msec and prolongation from baseline >60 msec, withhold ETCAMAH. If other contributing causes are identified, then treat or correct the contributing causes. Resume ETCAMAH when QTc returns to <480 msec. Reassess ECGs weekly for the first 2 weeks of treatment, and periodically during treatment as clinically indicated. Permanently discontinue ETCAMAH if QTc interval prolongation is either >500 msec or >60 msec change from baseline AND associated with any: TdP, polymorphic ventricular tachycardia, syncope, or signs/symptoms of serious arrhythmia.
Bradycardia: ETCAMAH causes a decrease in HR. Bradycardia increases the risk for life-threatening arrhythmias and sudden death when concomitant QTc interval prolongation is present, such as when ETCAMAH is used in combination with ribociclib, both a QTc interval prolonging product and a strong CYP3A inhibitor. In SERENA-6, bradycardia occurred in 8% of patients. The mean HR decrease from baseline was approximately 13 beats per minute (bpm) with the maximum decrease observed on day 15. Median time to onset was 17 days (range 13 to 283) after starting ETCAMAH. No patients discontinued ETCAMAH due to bradycardia. Dose interruption occurred in 3.9% of patients. The safety of ETCAMAH has not been established in patients with a baseline resting HR <55 bpm as these patients were excluded from SERENA-6. Monitor HR more frequently during the first 30 days of treatment in patients with bradycardia (HR <60 bpm) at baseline and those on concomitant medications known to lower HR (eg, beta-blockers).
For symptomatic (Grade 2 or above) bradycardia, withhold ETCAMAH until symptoms resolve. Obtain ECG to evaluate etiology. If a contributing concomitant medication is identified, modify the dosage or discontinue this medication, as appropriate, until bradycardia symptoms resolve, then resume ETCAMAH. Consider reassessing the HR after restart. Permanently discontinue for persistent symptomatic bradycardia.
Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, ETCAMAH can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with ETCAMAH and for 4 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ETCAMAH and for 1 week after the last dose.
ADVERSE REACTIONS
The most common (20%) adverse reactions, including laboratory abnormalities, with ETCAMAH in combination with a CDK4/6i were decreased neutrophils (68%), decreased leukocytes (66%), decreased hemoglobin (47%), decreased lymphocytes (39%), decreased platelets (36%), visual disturbances (34%), and fatigue (23%).
Permanent discontinuation due to adverse reactions occurred in 1.3% of patients. Adverse reactions that resulted in permanent discontinuation of ETCAMAH included gastroesophageal reflux disease, cholestasis and hepatic cytolysis (0.6% each). Dosage interruption of ETCAMAH due to adverse reactions occurred in 22% of patients.
Visual disturbances: For visual disturbances limiting instrumental ADLs (activities of daily living) (Grade 2) or above, withhold ETCAMAH until symptoms resolve to Grade 1 or below. Refer to an eye professional for an ophthalmic examination and treatment and reassess at the next visit.
For other Grade 3 or higher adverse reactions: Withhold ETCAMAH until resolution to Grade 2 or below, then resume. Permanently discontinue for recurrence of Grade 3 or higher adverse reactions.
DRUG INTERACTIONS
* Strong CYP3A Inhibitors: Monitor for increased adverse reactions to ETCAMAH and modify the dosage as recommended
* Strong and Moderate CYP3A Inducers: Avoid the use of strong CYP3A inducers. Use caution with the co-administration of a moderate CYP3A inducer
- Avoid concomitant use of moderate CYP3A inducers for patients who are receiving ETCAMAH in combination with abemaciclib or palbociclib. If concomitant use cannot be avoided, increase the ETCAMAH dosage from 75 mg once daily to 150 mg once daily. After the moderate CYP3A inducer has been discontinued for at least 14 days, resume the ETCAMAH dosage used prior to initiation of the moderate CYP3A inducer
- For patients who are receiving ETCAMAH in combination with ribociclib concomitantly with a moderate CYP3A inducer, no ETCAMAH dosage modification is recommended
* CYP2C9 and/or CYP2C19 Substrates: Avoid concomitant use of ETCAMAH with CYP2C9 or CYP2C19 substrates during treatment with ETCAMAH and at least 2 weeks after the last dose of ETCAMAH, unless otherwise recommended in the Prescribing Information of the CYP2C9 or CYP2C19 substrate
* Certain CYP3A Substrates: Refer to the Prescribing Information for CYP3A substrates where minimal increases in the concentration may lead to serious adverse reactions
* Drugs that Prolong the QTc Interval: ETCAMAH is indicated in combination with a CDK4/6i and there is increased risk of QTc interval prolongation with ribociclib, a strong CYP3A inhibitor that can prolong the QTc interval. Refer to the ribociclib Prescribing Information for dosage modifications. Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of TdP. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently. ETCAMAH in combination with a CDK4/6i is associated with QTc interval prolongation
* Drugs that Cause Bradycardia: Avoid concomitant use of ETCAMAH with other products known to cause bradycardia. Monitor for signs and symptoms of bradycardia if concomitant use cannot be avoided. ETCAMAH causes decreases in HR that are dose and baseline HR dependent
Refer to the Prescribing Information for the co-administered CDK4/6i for dosage modification guidelines related to adverse reactions, organ impairment, and drug-drug interactions.
SPECIAL POPULATIONS
Pregnancy: Based on findings in animals and mechanism of action, ETCAMAH can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
Lactation: Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ETCAMAH and for 1 week after the last dose.
Females and Males of Reproductive Potential: ETCAMAH can cause fetal harm when administered to pregnant women. Verify pregnancy status of female patients of reproductive potential prior to initiating ETCAMAH. Advise female patients of reproductive potential to use effective non-hormonal contraception during treatment with ETCAMAH and for 4 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ETCAMAH and for 1 week after the last dose. Refer to the Prescribing Information of the CDK4/6i palbociclib, if used in combination with ETCAMAH, for contraception information and use for the longest recommended post-treatment duration. ETCAMAH may impair fertility in female and male patients.
Pediatric Use: Safety and effectiveness have not been established in pediatric patients.
Hepatic Impairment: In patients with severe (Child-Pugh C) hepatic impairment, when ETCAMAH is combined with ribociclib, reduce the dosing frequency to every other day.
No dosage modifications are required in other patients with hepatic impairment of any level, or when ETCAMAH is combined with abemaciclib or palbociclib, although patients with moderate or severe hepatic impairment (Child-Pugh B or C) should be monitored for increased adverse reactions and dosage modified as recommended.
INDICATION
ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Please see full Prescribing Information (https://www.azpicentral.com/pi.html?product=etcamah), including Boxed WARNING, and Patient Information (https://www.azpicentral.com/pi.html?product=etcamah&medguide=y) for ETCAMAH.
* * *
Notes
HR-positive breast cancer
Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.9 More than two million patients were diagnosed with breast cancer in 2024, with more than 690,000 deaths globally.9 While survival rates are high for those diagnosed with early breast cancer, only about 30% of patients diagnosed with or who progress to metastatic disease are expected to live five years following diagnosis.6
HR-positive breast cancer, characterized by the expression of estrogen or progesterone receptors, or both, is the most common subtype of breast cancer with 70% of tumors considered HR-positive and HER2-negative.6 ERs often drive the growth of HR-positive breast cancer cells.10
Globally, more than 200,000 patients with HR-positive breast cancer are treated with a medicine in the 1st-line setting; most frequently with endocrine therapies that target ER-driven disease, which are often paired with CDK4/6 inhibitors.3-5
The optimization of endocrine therapy and overcoming resistance to enable patients to continue benefiting from these treatments, as well as identifying new therapies for those who are less likely to benefit, are active areas of focus for breast cancer research.
SERENA-6
SERENA-6 is a Phase III, double-blind, randomized trial evaluating the efficacy and safety of ETCAMAH in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with HR-positive, HER2-negative advanced breast cancer (patients with either locally advanced disease, or metastatic disease) whose tumors have an emergent ESR1 mutation.
The global trial enrolled 315 adult patients with histologically confirmed HR-positive, HER2-negative advanced breast cancer, undergoing treatment with an AI in combination with a CDK4/6 inhibitor as 1st-line treatment. The primary endpoint of the SERENA-6 trial is PFS as assessed by investigator, with secondary endpoints including OS, and PFS2 by investigator assessment.
ETCAMAH(R) (camizestrant)
ETCAMAH is a potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist, administered orally, once daily. The recommended dose of ETCAMAH in combination with a CDK4/6 inhibitor is 75 mg.
ETCAMAH in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) is approved in the US, EU, Japan and several other countries for the treatment of adult patients with HR-positive (or ER-positive), HER2-negative locally advanced or metastatic breast cancer upon detection or emergence of ESR1 mutation and without disease progression during 1st-line endocrine therapy based on the results from the SERENA-6 Phase III trial.
The broad, robust and innovative ETCAMAH clinical development program, including the SERENA-4, CAMBRIA-1 and CAMBRIA-2 Phase III trials, is evaluating the safety and efficacy of ETCAMAH when used as a monotherapy or in combination with CDK4/6 inhibitors to address a number of areas of unmet need in HR-positive, HER2-negative breast cancer.
* * *
AstraZeneca in breast cancer
Driven by a growing understanding of breast cancer biology, AstraZeneca is challenging, and redefining, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need - with the bold ambition to one day eliminate breast cancer as a cause of death.
AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumor environment.
With fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines fulvestrant and goserelin and aims to reshape the HR-positive space with first-in-class AKT inhibitor, capivasertib, the TROP-2-directed ADC, datopotamab deruxtecan-dlnk and next-generation oral SERD, ETCAMAH.
PARP inhibitor olaparib is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to research olaparib in these settings. AstraZeneca is also exploring the potential of saruparib, a potent and selective inhibitor of PARP1, in combination with ETCAMAH in BRCA-mutated, HR-positive, HER2-negative advanced breast cancer.
To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is collaborating with Daiichi Sankyo to evaluate the potential of datopotamab deruxtecan-dlnk alone and in combination with immunotherapy durvalumab.
* * *
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
* * *
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.
* * *
References
1. Bidard FC, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med 2025; DOI: 10.1056/NEJMoa2502929.
2. American Cancer Society. Key Statistics for Breast Cancer. Available at: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html. Accessed September 2026.
3. Cerner CancerMPact database. Accessed September 2026.
4. Lin M, et al. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer. 2020; 10.7150/jca.48944.
5. Lloyd M R, et al. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022; 28(5):821-30.
6. National Cancer Institute. Cancer Stat facts: Female breast cancer subtypes. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed September 2026.
7. Brett O, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor positive breast cancer. Breast Cancer Res. 2021; 23:85.
8. Zundelevich A, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020; 22:16.
9. Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026; DOI: 10.3322/caac.70090.
10. Scabia V, et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nat Commun. 2022; 10.1038/s41467-022-30898-0.
* * *
Original text here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/ETCAMAH-camizestrant-in-combination-with-a-CDK-4-6-inhibitor-approved-in-the-US-for-1st-line-advanced-HR-positive-breast-cancer.html
[Category: BizPharmaceuticals]
Dentons Advises Equans UK & Ireland on Its Acquisition of Mway Communications
WASHINGTON, Sept. 5 -- Dentons, a law firm, issued the following news:
* * *
Dentons advises Equans UK & Ireland on its acquisition of Mway Communications
London--Dentons has advised Equans UK & Ireland on its strategic acquisition of Mway Communications, a leading specialist in highways technology and communications infrastructure.
Mway provides critical technology and engineering solutions to National Highways and Tier 1 contractors across the UK's Strategic Road Network. The business employs around 100 people and generates annual turnover of approximately pound sterling26 million.
The acquisition ... Show Full Article WASHINGTON, Sept. 5 -- Dentons, a law firm, issued the following news: * * * Dentons advises Equans UK & Ireland on its acquisition of Mway Communications London--Dentons has advised Equans UK & Ireland on its strategic acquisition of Mway Communications, a leading specialist in highways technology and communications infrastructure. Mway provides critical technology and engineering solutions to National Highways and Tier 1 contractors across the UK's Strategic Road Network. The business employs around 100 people and generates annual turnover of approximately pound sterling26 million. The acquisitionstrengthens Equans' UK capabilities in connected infrastructure, operational technology and communications networks. Mway's services span technology deployment, electrical engineering, street lighting, traffic signals, inductive loop installation and highways civil works, complementing Equans' existing capabilities across digital infrastructure, energy systems, engineering and asset management.
James Graham, Divisional CEO at Equans UK & Ireland, said: "Mway Communications has built an excellent reputation as a trusted delivery partner across the UK's Strategic Road Network. Their deep sector knowledge and proven customer partnerships make them excellent in their operation. We are delighted to welcome the Mway team to Equans. We would also like to thank the Dentons team for the commercial and pragmatic advice throughout the transaction."
Chris Colclough, Partner in Dentons' UK Corporate team, said: "We are delighted to have supported Equans on this strategic acquisition. Mway is a high-quality business operating at the heart of the UK's critical highways infrastructure, and its specialist technology and engineering capabilities make it a compelling addition to Equans' existing platform. The transaction reflects the continued investment we are seeing in connected and technology-enabled infrastructure across the UK. It was a real pleasure to work with the Equans team and support them in delivering the acquisition."
The Dentons team was led by Chris Colclough, Partner and Head of the Milton Keynes Corporate team, supported by Senior Associate Chris Northway, Associate Emily Bowler and Trainee Mayowa Olagunju, working alongside a multidisciplinary team of Dentons specialists including Rukia Khatun and Lily Folland (Technology, Media and Telecommunications), Jamie MacGregor (Tax), Verity Buckingham (Employment) and Chris De Luca (Real Estate).
* * *
About Dentons
Redefining possibilities. Together, everywhere. For more information visit dentons.com
* * *
URL: Equans UK & Ireland
* * *
Original text here: https://www.dentons.com/en/about-dentons/news-events-and-awards/news/2026/september/dentons-advises-equans-uk-and-ireland-on-acquisition-of-mway-communications
[Category: BizLaw/Legal]
* * *
Dentons advises Equans UK & Ireland on its acquisition of Mway Communications
London--Dentons has advised Equans UK & Ireland on its strategic acquisition of Mway Communications, a leading specialist in highways technology and communications infrastructure.
Mway provides critical technology and engineering solutions to National Highways and Tier 1 contractors across the UK's Strategic Road Network. The business employs around 100 people and generates annual turnover of approximately pound sterling26 million.
The acquisition ... Show Full Article WASHINGTON, Sept. 5 -- Dentons, a law firm, issued the following news: * * * Dentons advises Equans UK & Ireland on its acquisition of Mway Communications London--Dentons has advised Equans UK & Ireland on its strategic acquisition of Mway Communications, a leading specialist in highways technology and communications infrastructure. Mway provides critical technology and engineering solutions to National Highways and Tier 1 contractors across the UK's Strategic Road Network. The business employs around 100 people and generates annual turnover of approximately pound sterling26 million. The acquisitionstrengthens Equans' UK capabilities in connected infrastructure, operational technology and communications networks. Mway's services span technology deployment, electrical engineering, street lighting, traffic signals, inductive loop installation and highways civil works, complementing Equans' existing capabilities across digital infrastructure, energy systems, engineering and asset management.
James Graham, Divisional CEO at Equans UK & Ireland, said: "Mway Communications has built an excellent reputation as a trusted delivery partner across the UK's Strategic Road Network. Their deep sector knowledge and proven customer partnerships make them excellent in their operation. We are delighted to welcome the Mway team to Equans. We would also like to thank the Dentons team for the commercial and pragmatic advice throughout the transaction."
Chris Colclough, Partner in Dentons' UK Corporate team, said: "We are delighted to have supported Equans on this strategic acquisition. Mway is a high-quality business operating at the heart of the UK's critical highways infrastructure, and its specialist technology and engineering capabilities make it a compelling addition to Equans' existing platform. The transaction reflects the continued investment we are seeing in connected and technology-enabled infrastructure across the UK. It was a real pleasure to work with the Equans team and support them in delivering the acquisition."
The Dentons team was led by Chris Colclough, Partner and Head of the Milton Keynes Corporate team, supported by Senior Associate Chris Northway, Associate Emily Bowler and Trainee Mayowa Olagunju, working alongside a multidisciplinary team of Dentons specialists including Rukia Khatun and Lily Folland (Technology, Media and Telecommunications), Jamie MacGregor (Tax), Verity Buckingham (Employment) and Chris De Luca (Real Estate).
* * *
About Dentons
Redefining possibilities. Together, everywhere. For more information visit dentons.com
* * *
URL: Equans UK & Ireland
* * *
Original text here: https://www.dentons.com/en/about-dentons/news-events-and-awards/news/2026/september/dentons-advises-equans-uk-and-ireland-on-acquisition-of-mway-communications
[Category: BizLaw/Legal]